open access

Vol 72, No 4 (2021)
Original paper
Submitted: 2021-02-21
Accepted: 2021-05-16
Early publication date: 2021-06-08
Get Citation

Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues

Paweł Gut1, Agata Czarnywojtek2, Nadia Sawicka-Gutaj1, Kosma Woliński1, Adam Maciejewski1, Paweł Komarnicki1, Marek Ruchała1
DOI: 10.5603/EP.a2021.0060
·
Pubmed: 34292567
·
Endokrynol Pol 2021;72(4):308-318.
Affiliations
  1. Department of Endocrinology, Metabolism, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Pharmacology, Poznan University of Medical Sciences, Poznan, Poland

open access

Vol 72, No 4 (2021)
Original Paper
Submitted: 2021-02-21
Accepted: 2021-05-16
Early publication date: 2021-06-08

Abstract

Introduction: The biochemical diagnosis of neuroendocrine tumours (NETs) uses assays of specific and nonspecific markers. Nonspecific markers include, among others, neuron-specific enolase (NSE). The aim of this study was to evaluate NSE in patients with midgut type tumours treated with somatostatin analogues.

Material and methods: The study group of patients with NETs of the small intestine included 41 patients. Grade G1 was found in 19 cases, while G2 was seen in the remaining 22 cases. Liver metastases were found in all patients studied. The examined group of patients was treated with somatostatin analogues receiving octreotide LAR at a dose of 30 mg. The control of biochemical parameters was performed every 3 months and imaging examinations every 6 months. The Immuno-Biological Laboratories kit was used for determination of NSE concentration, where reference values were 12.5–25 ng/mL.

Results: In the G1 group of patients, the median value of NSE concentration was 134.67 ng/mL, while in the G2 group, the value was 234.55 ng/mL and was significantly higher than in the G1 group (p = 0.003). In the determination of NSE concentration values according to the degree of liver involvement, in the group of patients with 10% liver involvement, the median value of NSE concentration was 143.21 ng/mL, while in the group with 25% liver involvement, the value was 251.82 ng/mL (p < 0.001). In the analysis of NSE concentration assessment in patients with disease progression, the median value was 234.65 ng/mL compared to the group with disease stabilization, where the median NSE value was significantly lower and amounted to 136.27 ng/mL (p < 0.001).

Conclusions: In our study, we observed that NSE concentration values were significantly higher among patients with NET midgut type tumour with histological grade G2 and in patients with 25% liver involvement and progression of the disease process.

Abstract

Introduction: The biochemical diagnosis of neuroendocrine tumours (NETs) uses assays of specific and nonspecific markers. Nonspecific markers include, among others, neuron-specific enolase (NSE). The aim of this study was to evaluate NSE in patients with midgut type tumours treated with somatostatin analogues.

Material and methods: The study group of patients with NETs of the small intestine included 41 patients. Grade G1 was found in 19 cases, while G2 was seen in the remaining 22 cases. Liver metastases were found in all patients studied. The examined group of patients was treated with somatostatin analogues receiving octreotide LAR at a dose of 30 mg. The control of biochemical parameters was performed every 3 months and imaging examinations every 6 months. The Immuno-Biological Laboratories kit was used for determination of NSE concentration, where reference values were 12.5–25 ng/mL.

Results: In the G1 group of patients, the median value of NSE concentration was 134.67 ng/mL, while in the G2 group, the value was 234.55 ng/mL and was significantly higher than in the G1 group (p = 0.003). In the determination of NSE concentration values according to the degree of liver involvement, in the group of patients with 10% liver involvement, the median value of NSE concentration was 143.21 ng/mL, while in the group with 25% liver involvement, the value was 251.82 ng/mL (p < 0.001). In the analysis of NSE concentration assessment in patients with disease progression, the median value was 234.65 ng/mL compared to the group with disease stabilization, where the median NSE value was significantly lower and amounted to 136.27 ng/mL (p < 0.001).

Conclusions: In our study, we observed that NSE concentration values were significantly higher among patients with NET midgut type tumour with histological grade G2 and in patients with 25% liver involvement and progression of the disease process.

Get Citation

Keywords

neuron-specific enolase; neuroendocrine tumours; midgut; somatostatin analogues

About this article
Title

Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues

Journal

Endokrynologia Polska

Issue

Vol 72, No 4 (2021)

Article type

Original paper

Pages

308-318

Early publication date

2021-06-08

Page views

448

Article views/downloads

299

DOI

10.5603/EP.a2021.0060

Pubmed

34292567

Bibliographic record

Endokrynol Pol 2021;72(4):308-318.

Keywords

neuron-specific enolase
neuroendocrine tumours
midgut
somatostatin analogues

Authors

Paweł Gut
Agata Czarnywojtek
Nadia Sawicka-Gutaj
Kosma Woliński
Adam Maciejewski
Paweł Komarnicki
Marek Ruchała

References (25)
  1. Caplin M, Kvols L. Handbook of neuroendocrine tumours, their current and future management. BioScientisica, Bristol 2006: 103–109.
  2. Wick MR, Scheithauer BW, Kovacs K. Neuron-specific enolase in neuroendocrine tumors of the thymus, bronchus, and skin. Am J Clin Pathol. 1983; 79(6): 703–707.
  3. Giovanella L, La Rosa S, Ceriani L, et al. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers. 1999; 14(3): 160–166.
  4. Kasprzak A, Zabel M, Biczysko W. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours. Pol J Pathol. 2007; 58(1): 23–33.
  5. Braga F, Ferraro S, Mozzi R, et al. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clin Biochem. 2013; 46(1-2): 148–151.
  6. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol. 2001; 22(4): 309–339.
  7. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000; 62 Suppl 1: 33–38.
  8. Eberlein-Gonska M, Wiedenmann B, Waldherr R. [Synaptophysin, chromogranin A and neuron-specific enolase as tumor markers in neuroendocrine tumors of the gastrointestinal tract and lung. An immunohistochemical study]. Pathologe. 1989; 10(4): 228–233.
  9. Manfé AZ, Norberto L, Marchesini M, et al. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids. In Vivo. 2011; 25(6): 1027–1029.
  10. Dittadi R, Gion M. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clin Biochem. 2013; 46(12): 1145.
  11. Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. [Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. Endokrynol Pol. 2008; 59(1): 41–56.
  12. Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Neuroendocrine neoplasms of the small intestine and the appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 480–493.
  13. Landry CS, Cavaness K, Celinski S, et al. Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors. Gland Surg. 2014; 3(4): 215–218.
  14. van Adrichem RCS, Kamp K, Vandamme T, et al. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol. 2016; 27(4): 746–747.
  15. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci. 1994; 733: 416–424.
  16. Bocchini M, Nicolini F, Severi S, et al. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol. 2020; 10: 831.
  17. Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867: 125–143.
  18. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997; 82(8): 2622–2628.
  19. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998; 78(8): 1102–1107.
  20. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011; 96(12): 3741–3749.
  21. Korse CM, Taal BG, Vincent A, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012; 48(5): 662–671.
  22. Kaiser E, Kuzmits R, Pregant P, et al. Clinical biochemistry of neuron specific enolase. Clin Chim Acta. 1989; 183(1): 13–31.
  23. Mjønes P, Sagatun L, Nordrum IS, et al. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation. J Histochem Cytochem. 2017; 65(12): 687–703.
  24. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999; 86(5): 858–865, doi: 10.1002/(sici)1097-0142(19990901)86:5<858::aid-cncr23>3.0.co;2-8.
  25. Manfé AZ, Norberto L, Marchesini M, et al. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids. In Vivo. 2011; 25(6): 1027–1029.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl